PTPRC and neoplasm: Neither genetic deficiency of CCR2 nor a small-molecule inhibitor of CCR2 (CCX872) showed any efficacy in extending the survival time of tumor-bearing mice compared with WT or vehicle-treated mice, despite significant reductions of CCR2+ monocyte and CD45+CD11B+ myeloid infiltration into tumors (123).